ERBB2 and neoplasm: Also, longer overall survival time were seen in patients with poor tumor differentiation (HR, 0.73 95% CI [0.54–0.99]; P = 0.046), II-IIIB tumor stage (HR, 0.71, 95% CI [0.51–0.98]; P = 0.035) and negative HER-2 expression (HR, 0.74, 95% CI [0.55–1.00]; P = 0.050) (Fig. 4B).